Kantarjian H M, Keating M J, Walters R S, McCredie K B, Bodey G P, Freireich E J
Cancer. 1986 Oct 15;58(8):1603-8. doi: 10.1002/1097-0142(19861015)58:8<1603::aid-cncr2820580804>3.0.co;2-s.
Forty-one previously untreated patients with a diagnosis of acute myelogenous leukemia (AML) were entered on a study using early intensification followed by a short-term maintenance chemotherapy. Induction and early intensification consisted of three to four cycles of doxorubicin, vincristine, cytosine arabinoside (Ara-C) and prednisone (ADOAP) in escalating dosages. Maintenance therapy used three cycles of Ara-C thioguanine (AT), followed by three cycles of cyclophosphamide and rubidazone with vincristine and prednisone (CROP). Median total duration of therapy was 9 months. The overall complete remission (CR) rate was 73%. Tolerance to chemotherapy and dose escalation were better for patients who received their induction and early intensification in the protected environment. The overall median survival was 75 weeks. Compared to a historical control group treated with long-term maintenance chemotherapy, patients achieving CR on the current study had similar median remission (52 versus 65 weeks; P = 0.3) and survival durations (94 versus 98 weeks). This regimen using early intensification and short-term maintenance chemotherapy did not improve the overall prognosis of this AML population.
41例初治的急性髓性白血病（AML）患者参与了一项研究，该研究采用早期强化治疗，随后进行短期维持化疗。诱导和早期强化治疗包括三到四个周期逐渐增加剂量的阿霉素、长春新碱、阿糖胞苷（Ara-C）和泼尼松（ADOAP）。维持治疗采用三个周期的阿糖胞苷硫鸟嘌呤（AT），随后是三个周期的环磷酰胺、柔红霉素联合长春新碱和泼尼松（CROP）。治疗的中位总时长为9个月。总体完全缓解（CR）率为73%。在保护环境中接受诱导和早期强化治疗的患者对化疗的耐受性和剂量增加情况更好。总体中位生存期为75周。与接受长期维持化疗的历史对照组相比，在当前研究中达到CR的患者中位缓解期（分别为52周和65周；P = 0.3）和生存期（分别为94周和98周）相似。这种采用早期强化和短期维持化疗的方案并未改善该AML人群的总体预后。
